These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 3857136

  • 21. [Pharmacokinetics of phenytoin in continuous ambulatory peritoneal dialysis. 2 cases and brief review of the literature].
    Hess B, Keusch G, Flückiger J, Binswanger U.
    Schweiz Med Wochenschr; 1984 Jan 07; 114(1):16-9. PubMed ID: 6695161
    [Abstract] [Full Text] [Related]

  • 22. Nitric oxide is a marker of peritonitis in patients on continuous ambulatory peritoneal dialysis.
    Choi KC, Jeong TK, Lee SC, Kim SW, Kim NH, Lee KY.
    Adv Perit Dial; 1998 Jan 07; 14():173-9. PubMed ID: 10649719
    [Abstract] [Full Text] [Related]

  • 23. The effects of increasing exchange volume and frequency on peritoneal dialysis adequacy.
    Gao H, Lew SQ, Bosch JP.
    Clin Nephrol; 1998 Dec 07; 50(6):375-80. PubMed ID: 9877111
    [Abstract] [Full Text] [Related]

  • 24. Pharmacokinetics of ceftizoxime in patients undergoing hemodialysis.
    Shah PM, Knobloch M, Haag R, Kühnle HF.
    Methods Find Exp Clin Pharmacol; 1982 Dec 07; 4(3):185-8. PubMed ID: 6289027
    [Abstract] [Full Text] [Related]

  • 25. Plasma and peritoneal endothelin levels and blood pressure in CAPD patients with or without erythropoietin replacement therapy.
    Lebel M, Moreau V, Grose JH, Kingma I, Langlois S.
    Clin Nephrol; 1998 May 07; 49(5):313-8. PubMed ID: 9617496
    [Abstract] [Full Text] [Related]

  • 26. A drug-induced turbid peritoneal dialysate in five patients treated with continuous ambulatory peritoneal dialysis.
    Yoshimoto K, Saima S, Echizen H, Nakamura Y, Ishizaki T.
    Clin Nephrol; 1993 Aug 07; 40(2):114-7. PubMed ID: 8222367
    [Abstract] [Full Text] [Related]

  • 27. [Transperitoneal resorption of cefotiam in CAPD patients with and without peritonitis].
    Thomae U, Koblinger S.
    Med Klin (Munich); 1994 Sep 15; 89(9):464-8. PubMed ID: 7968880
    [Abstract] [Full Text] [Related]

  • 28. Cefotaxime and metabolite disposition in two pediatric continuous ambulatory peritoneal dialysis patients.
    Paap CM, Nahata MC, Mentser MA, Mahan JD, Puri SK, Hubbard JA.
    Ann Pharmacother; 1992 Mar 15; 26(3):341-3. PubMed ID: 1554953
    [Abstract] [Full Text] [Related]

  • 29. [Pharmacokinetics of ceftazidime injected peritoneally in continuous ambulatory peritoneal dialysis].
    Ryckelynck JP, Vergnaud M, Hurault de Ligny B, Allouche G, Malbruny B, Morel C.
    Pathol Biol (Paris); 1986 May 15; 34(5):328-31. PubMed ID: 3534700
    [Abstract] [Full Text] [Related]

  • 30. Estimating the daily dialysate drain volume required in CAPD for a target peritoneal creatinine clearance by body water and peritoneal transport characteristics.
    Rao P, Tzamaloukas AH, Murata GH, Piraino B, Malhotra D, Bernardini J, Oreopoulos DG.
    Adv Perit Dial; 1997 May 15; 13():33-7. PubMed ID: 9360647
    [Abstract] [Full Text] [Related]

  • 31. Pharmacokinetics of cefdinir and its transfer to dialysate in patients with chronic renal failure undergoing continuous ambulatory peritoneal dialysis.
    Tomino Y, Fukui M, Hamada C, Inoue S, Osada S.
    Arzneimittelforschung; 1998 Aug 15; 48(8):862-7. PubMed ID: 9748717
    [Abstract] [Full Text] [Related]

  • 32. Pharmacokinetics of procainamide in continuous ambulatory peritoneal dialysis.
    Sica DA, Yonce C, Small R, Cefali E, Harford A, Poynor W.
    Int J Clin Pharmacol Ther Toxicol; 1988 Feb 15; 26(2):59-64. PubMed ID: 2457560
    [Abstract] [Full Text] [Related]

  • 33. Disposition of cefotaxime and desacetyl cefotaxime during continuous ambulatory peritoneal dialysis.
    Heim KL, Halstenson CE, Comty CM, Affrime MB, Matzke GR.
    Antimicrob Agents Chemother; 1986 Jul 15; 30(1):15-9. PubMed ID: 3752976
    [Abstract] [Full Text] [Related]

  • 34. Ofloxacin pharmacokinetics in patients on continuous ambulatory peritoneal dialysis.
    Chan MK, Chau PY, Chan WW.
    Clin Nephrol; 1987 Dec 15; 28(6):277-80. PubMed ID: 3481692
    [Abstract] [Full Text] [Related]

  • 35. Pharmacokinetics of ceftizoxime.
    Cutler RE, Blair AD, Burgess ED, Parks D.
    J Antimicrob Chemother; 1982 Nov 15; 10 Suppl C():91-7. PubMed ID: 6296034
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Effect of hemodialysis and peritoneal dialysis on aztreonam pharmacokinetics.
    Gerig JS, Bolton ND, Swabb EA, Scheld WM, Bolton WK.
    Kidney Int; 1984 Sep 15; 26(3):308-18. PubMed ID: 6542606
    [Abstract] [Full Text] [Related]

  • 39. Phase I study of ceftizoxime, a new cephalosporin. Single-dose study.
    Nakashima N, Suzuki K, Hashimoto H, Nishijima K.
    J Clin Pharmacol; 1981 Oct 15; 21(10):388-95. PubMed ID: 6273456
    [Abstract] [Full Text] [Related]

  • 40. Pharmacokinetics of intravenous and intraperitoneal moxalactam in chronic ambulatory peritoneal dialysis.
    Albin H, Ragnaud JM, Demotes-Mainard F, Vincon G, Wone C.
    Eur J Clin Pharmacol; 1986 Oct 15; 30(3):299-302. PubMed ID: 3732364
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.